Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 2013

View Archived Issues

Servier partners with SIgN for immunomodulatory drugs

Sanofi's Complavin combination tablets approved in Japan

Stanford University presents 64Cu-NOTA-B-Fab, an immuno-PET tracer companion diagnostic

Proximagen begins phase II PRX-167700 study of knee osteoarthritis

Phase III study of BioMarin's BMN-673 in metastatic breast cancer commences

Bioheart forms license agreement with Invitrx

Cornerstone Pharmaceuticals begins phase II CPI-613 trial in MDS

Torrent Pharmaceuticals presents first clinical data for TRC-150094

Gemigliptin is safe and efficient as a long-term treatment added to ongoing metformin

DatSCAN intravenous injection approved in Japan

Ablynx and Merck Serono expand nanobodies partnership

Program to evaluate LUM-001 in Alagille syndrome, FDA grants LUM-001 orphan drug designations

Merck KGaA to renew testing of lung cancer vaccine

Tetra Discovery receives phase II SBIR grant to develop new depression drug

Bio-Matrix Scientific provides update on dCellVax for breast cancer

Novo Nordisk files application to expand approval of liraglutide in Japan

Mologen submits MGN-1703 IND application with FDA

Simeprevir obtains first approval in Japan

CSL Behring gains Japanese approval for Hizentra

Alnylam Pharmaceuticals reports interim results from phase I ALN-TTRsc trial

Experimental LTC4S gene overexpression replicates aspirin-induced asthma

TNF-alpha production inhibitors reported by PuraPharm and Versitech

Lupin discovers nAChR alpha7 modulators

Cadila Healthcare divulges discovery of PCSK9 inhibitors

Merck & Co. prepares and tests novel PAR-1 antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...